ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2047

No Association of Serum Uric Acid with Hip Fracture Risk in Older Men and Women from the Framingham Original Cohort

Shivani Sahni1, Kelsey Mangano2, Katherine Tucker3, Caroline Fox4, Douglas P. Kiel5, Xiaochun Zhang6 and Marian T. Hannan1, 1Institute for Aging Research, Hebrew SeniorLife, Dept. of Medicine Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 2Musculoskeletal Research, Institute for Aging Research, Hebrew SeniorLife, Dept. of Medicine Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 3Clinical Laboratory & Nutritional Sciences, Center for Population Health & Health Disparities, University of Massachusetts, Lowell, MA, 4Institute of Genetics and Biophysics, NHLBI's Framingham Heart Study and Center for Population Studies, Framingham, MA, 5Institute for Aging Research, Hebrew SeniorLife, Dept. of Medicine Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 6Musculoskeletal Research, Institute for Aging Research, Hebrew SeniorLife, Roslindale, MA

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Elderly, Fracture risk, longitudinal studies, osteoporosis and uric acid

  • Tweet
  • Email
  • Print
Session Information

Title: Epidemiology and Public Health (ARHP)

Session Type: Abstract Submissions (ARHP)

Background/Purpose:   Serum uric acid (UA) has been linked with fractures in older men. Three different studies in older men showed conflicting results. The objective of this study was to examine the association of UA with hip fracture risk over 19.9y follow-up in men and women from the Framingham Original Cohort. 

Methods:  2,969 men & women had measured UA concentration (mg/dl) at baseline (1973-76) and were followed for hip fracture until 2009. We used Cox-proportional hazards regression to estimate Hazard Ratios (HR) adjusting for age, sex and menopausal status (men, pre- and post-menopausal women), weight and height. An interaction between UA and sex was tested. Analysis was conducted on a combined sample of men and women, if the interaction term was not significant (P>0.05).

Results:  The mean age was 66y (SD: 7.7, range: 53-85). 368 hip fractures occurred over the follow-up (mean of 19.9 years). The mean ± SD (mg/dl) uric acid at baseline was: 5.3 ± 1.4. Interaction between UA and sex was not statistically significant (P=0.72); therefore, men and women were analyzed together. An increase in one unit of UA was associated with a 7% decrease in hip fracture risk in the crude model [HR(95%CI): 0.93 (0.86-1.0); P=0.048]. Similar associations were observed when UA was analyzed as tertile categories (P-trend: 0.08). Participants in the highest tertile of UA [HR (95%CI):0.79 (0.61-1.03)] tended to have lower risk of hip fracture than those in the lowest tertile (P=0.08).These associations became non-significant after adjustment for covariates.

Conclusion: These results suggest that serum UA is not a risk factor for hip fracture risk in older adults. 

Table. Association of serum uric acid (mg/dl) with risk of hip fracture in men and women. 

 

N

HR(95% CI)

P-value

Crude

2,969

0.93(0.86,1.0)

0.048*

Adjusted1

2,966

1.01(0.93,1.1)

0.850

1Adjusted for: age, sex and menopausal status (men, pre-menopausal women, post-menopausal women), height and weight, *P<0.05.

Funding support: The ASBMR JFOR201314 Award, NIH/NIAMS R03 AR 062808, NIH AR # 053205; FHS N01-HC-25195 R01 AR/AG 41398


Disclosure:

S. Sahni,
None;

K. Mangano,
None;

K. Tucker,
None;

C. Fox,
None;

D. P. Kiel,

Springer for editorial work and author royalties from UpToDate®.,

7,

Institutional grants from Merck Sharp and Dohme, Amgen, Eli Lilly ,

2,

Merck Sharp and Dohme, Amgen, Eli Lilly, Ammonett Pharma and Novartis,

9;

X. Zhang,
None;

M. T. Hannan,
None.

  • Tweet
  • Email
  • Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/no-association-of-serum-uric-acid-with-hip-fracture-risk-in-older-men-and-women-from-the-framingham-original-cohort/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology